High density lipoprotein cholesterol in coronary artery disease: When higher means later

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 1, 2013, Pages 23-31

  Sbrana, Francesco ^a   Puntoni, Mariarita ^b   Bigazzi, Federico ^a   Landi, Patrizia ^b   Sampietro, Tiziana ^a   Rossi, Giuseppe ^b   Rovai, Daniele ^a,b  

^a FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Age; Atherosclerosis; Coronary artery disease; High density lipoprotein cholesterol; Prognosis

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY;

AGED; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84873732268     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13201     Document Type: Article

References (43)

1. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J: Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009; 302: 1993-2000.
2. Yokokawa H, Yasumura S, Tanno K, Ohsawa M, Onoda T, Itai K, Sakata K, Kawamura K, Tanaka F, Yoshida Y, Nakamura M, Terayama Y, Ogawa A, Okayama A: Serum low-density lipoprotein to high-density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population. J Atheroscler Thromb, 2011; 18: 89-98.
3. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011; 32: 1345-1361.
4. Yokoyama S, Yamashita S, Ishibashi S, Sone H, Oikawa S, Shirai K, Ohta T, Bujo H, Kobayashi J, Arai H, Harada- Shiba M, Eto M, Hayashi T, Gotoda T, Suzuki H, Yamada N: Background to Discuss Guidelines for Control of Plasma HDL-Cholesterol in Japan. J Atheroscler Thromb, 2012 Jan 12.
5. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 2007; 357: 1301-1310.
6. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681.
7. Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM, Park CS, Kim PJ, Moon KW, Chang K, Kim HY, Yoo KD, Jeon DS, Chung WS, Park YG, Seung KB: Catholic University of Korea, Percutaneous Coronary Intervention Registry investigators. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving lowdensity lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart, 2011; 97: 1943-1950.
8. Shiga Y, Miura S, Mitsutake R, Kawamura A, Uehara Y, Saku K: Significance of serum high-density lipoprotein cholesterol levels for diagnosis of coronary stenosis as determined by MDCT in patients with suspected coronary artery disease. J Atheroscler Thromb, 2010; 17: 870-878.
9. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A: Highdensity lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J, 2005; 26: 890-896.
10. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS): ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011; 217: 3-46.
11. Hirano K, Yamashita S, Kuga Y, Sakai N, Nozaki S, Kihara S, Arai T, Yanagi K, Takami S, Menju M, Ishigami M, Yoshida Y, Kameda-Takemura K, Hayashi K, Matsuzawa Y: Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol, 1995; 15: 1849-1856.
12. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y: Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol, 1997; 17: 1053-1059.
13. Nagano M, Yamashita S, Hirano K, Takano M, Maruyama T, Ishihara M, Sagehashi Y, Kujiraoka T, Tanaka K, Hattori H, Sakai N, Nakajima N, Egashira T, Matsuzawa Y: Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb, 2004; 11: 110-121.
14. Cefalù AB, Noto D, Magnolo L, Pinotti E, Gomaraschi M, Martini S, Vigna GB, Calabresi L, Tarugi P, Averna MR: Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. Atherosclerosis, 2009; 204: 202-207.
15. Calabresi L, Nilsson P, Pinotti E, Gomaraschi M, Favari E, Adorni MP, Bernini F, Sirtori CR, Calandra S, Franceschini G, Tarugi P: A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis, 2009; 205: 506-511.
16. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, 1998; 21: 518-524.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003; 289: 2560-2572.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary on the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment on High Blood Cholesterol in Adults (adult treatment panel III). JAMA, 2001; 285: 2486-2497.
19. National Institutes of Health. Evidence-Based Guidelines: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: Executive Summary. Bethesda, MD: National Heart, Lung and Blood Institute, 2002.
20. Gimelli A, Rossi G, Landi P, Marzullo P, Iervasi G, L'Abbate A, Rovai D: Stress/rest myocardial perfusion abnormalities by gated SPECT: Still the best predictor of cardiac events in stable ischemic heart disease. J Nucl Med, 2009; 50: 546-553.
21. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 309: 499-502.
22. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L'Abbate A, Pingitore A: Association between increased mortality and mild thyroid dysfunction in car- diac patients. Arch Intern Med, 2007; 167: 1526-1532.
23. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L: Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 2003; 107: 708-713.
24. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004; 110: 227-239.
25. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97: 1837-1847.
26. Randomise trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389.
27. TheLong-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357.
28. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-then-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet, 2003; 361: 1149-1158.
29. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group: PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet, 2002; 360: 1623-1630.
30. Baigen C, Keech A, Kearney PM, Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trial of statins. Lancet, 2005; 366: 1267-1278.
31. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 1977; 62: 707-714.
32. Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the PROCAM Study. Circulation, 2002; 105: 310-315.
33. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007; 298: 309-316.
34. Nordestgaard BG, Benn M, Ashnohr P, Tybyaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infraction, ischemic heart disease, and death in men and women. JAMA, 2007; 297: 299-308.
35. deGoma EM, Leeper NJ, Heidenreich PA: Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol, 2008; 51: 49-55.
36. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med, 2011; 364: 127-135.
37. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE: Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis, 2006; 187: 191-197.
38. Costacou T, Evans RW, Orchard TJ: High-density lipoprotein cholesterol in diabetes: Is higher always better? J Clin Lipidol, 2011; 5: 387-394.
39. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ: The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med, 2001; 11(3-4): 155-161.
40. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis, 2002; 161: 1-16.
41. Francis GA: The complexity of HDL. Biochim Biophys Acta, 2010; 1801: 1286-1293.
42. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M: Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb, 2010; 17: 436-451.
43. Mora S, Buring JE, Ridker PM, Cui Y: Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein b100 levels: a cohort study. Ann Intern Med, 2011; 155: 742-750